NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Henderson JT, Webber EM, Sawaya GF. Screening for Ovarian Cancer: An Updated Evidence Review for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Feb. (Evidence Synthesis, No. 157.)
Screening for Ovarian Cancer: An Updated Evidence Review for the U.S. Preventive Services Task Force [Internet].
Show details| Trial, Year of publication | UKCTOCS, 2016 (CA-125 ROCA arm)92 | UKCTOCS, 2016 (ultrasound arm)92 | PLCO, 201191 | U.K. Pilot, 199998 |
|---|---|---|---|---|
| Quality | Good | Good | Good | Good |
| N analyzed per arm | IG: 50,624 CG: 101,299 | IG: 50,623 CG: 101,299 | IG: 34,253 CG: 34,304 | IG: 10,958 CG: 10,977 |
| Ovarian cancer incidence, n (%) | IG: 338 (0.7) CG: 630 (0.6) | IG: 314 (0.6) CG: 630 (0.6) | IG: 183 (0.5) CG: 158 (0.5) | IG: 16 (0.1) CG: 20 (0.2) |
| Ovarian cancer incidence rate | IG: 6.2 per 10,000 p-y CG: 5.7 per 10,000 p-y | IG: 5.7 per 10,000 p-y CG: 5.7 per 10,000 p-y | IG: 4.9 per 10,000 p-y CG: 4.7 per 10,000 p-y | NR |
| Between group difference | p=NR | p=NR | p=NR | |
| Ovarian cancer mortality, n (%) | IG: 148 (0.29) CG: 347 (0.34) | IG: 163 (0.30) CG: 347 (0.34) | NR | IG: 9 (0.082) CG: 18 (0.16) |
| Ovarian cancer mortality rate | IG: 2.7 per 10,000 p-y CG: 3.2 per 10,000 p-y | IG: 2.8 per 10,000 p-y CG: 3.2 per 10,000 p-y | NR | NR |
| Ovarian cancer mortality between group difference | HR: 0.85 (95% CI, 0.70 to 1.03), p=0.10† | HR: 0.89 (0.73, 1.07), p=0.21† | NR | RR: 0.50 (95% CI, 0.22 to 1.11) p=0.083‡ |
- *
Includes ovarian and fallopian cancers
- †
Cox proportional hazards model
- ‡
Calculated (article reports RR calculated in in terms of increased relative risk)
Abbreviations: CG = control group; CI = confidence interval; HR = hazard ratio; IG = intervention group; NR = not reported; NS = not significant; PLCO = Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; P-Y = person-years; ROCA = Risk of Ovarian Cancer Algorithm; RR = relative risk; U.K. = United Kingdom; UKCTOCS: U.K. Collaborative Trial of Ovarian Cancer Screening
- Benefits Reported in Ovarian Cancer Screening Trials: Ovarian Cancer Mortality i...Benefits Reported in Ovarian Cancer Screening Trials: Ovarian Cancer Mortality in Analyses Excluding Peritoneal Cancer* - Screening for Ovarian Cancer
- Sorex caecutiens voucher NED 232/2007 cytochrome b gene, complete cds; mitochond...Sorex caecutiens voucher NED 232/2007 cytochrome b gene, complete cds; mitochondrialgi|2727467305|gb|OQ995257.1|Nucleotide
- CAB1 chlorophyll A/B binding protein 1 [Arabidopsis thaliana]CAB1 chlorophyll A/B binding protein 1 [Arabidopsis thaliana]Gene ID:839871Gene
Your browsing activity is empty.
Activity recording is turned off.
See more...